0001209191-23-049999.txt : 20230919
0001209191-23-049999.hdr.sgml : 20230919
20230919170506
ACCESSION NUMBER: 0001209191-23-049999
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230918
FILED AS OF DATE: 20230919
DATE AS OF CHANGE: 20230919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fiedorek Fred T.
CENTRAL INDEX KEY: 0001657185
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 231264584
MAIL ADDRESS:
STREET 1: 55 BALDWIN LANE
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-18
0
0001840574
Verve Therapeutics, Inc.
VERV
0001657185
Fiedorek Fred T.
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
0
1
0
0
Chief Medical Officer
0
Stock Option (right to buy)
12.71
2023-09-18
4
A
0
180000
0.00
A
2033-09-17
Common Stock
180000
180000
D
The option was granted on September 18, 2023. 25% of the shares underlying the option will vest on September 18, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until September 18, 2027.
/s/ Andrew Ashe, Attorney-in-Fact for Fred T. Fiedorek
2023-09-19